Maximus: A Discount To Peers, Even If The Recent Contract Change Is Permanent
Maximus lowered its fiscal 2026 adjusted EPS guidance to $7.90-$8.20 after the VA paused performance incentive payments in its medical exam program from July through December 2026. The article notes that even without those incentives, MMS still trades at a discount to its peers on earnings and cash flow metrics.
Why it matters — A MMS watcher would care because the VA incentive-payment pause weighs on near-term earnings, yet the article highlights that the stock still trades below peers while offering the lowest leverage and a 15% free cash flow yield.